Spyre Therapeutics (SYRE) Income towards Parent Company: 2015-2025
Historic Income towards Parent Company for Spyre Therapeutics (SYRE) over the last 11 years, with Sep 2025 value amounting to -$11.2 million.
- Spyre Therapeutics' Income towards Parent Company rose 83.80% to -$11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.0 million, marking a year-over-year increase of 30.68%. This contributed to the annual value of -$208.0 million for FY2024, which is 38.60% up from last year.
- Per Spyre Therapeutics' latest filing, its Income towards Parent Company stood at -$11.2 million for Q3 2025, which was up 69.54% from -$36.7 million recorded in Q2 2025.
- In the past 5 years, Spyre Therapeutics' Income towards Parent Company ranged from a high of -$11.2 million in Q3 2025 and a low of -$217.1 million during Q2 2023.
- In the last 3 years, Spyre Therapeutics' Income towards Parent Company had a median value of -$43.9 million in 2024 and averaged -$58.1 million.
- In the last 5 years, Spyre Therapeutics' Income towards Parent Company tumbled by 872.45% in 2023 and then soared by 83.80% in 2025.
- Quarterly analysis of 5 years shows Spyre Therapeutics' Income towards Parent Company stood at -$20.4 million in 2021, then increased by 7.94% to -$18.8 million in 2022, then crashed by 235.67% to -$63.2 million in 2023, then increased by 10.90% to -$56.3 million in 2024, then surged by 83.80% to -$11.2 million in 2025.
- Its last three reported values are -$11.2 million in Q3 2025, -$36.7 million for Q2 2025, and -$44.8 million during Q1 2025.